Dublin, OH, United States of America

Frank Segrave

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 8.0

ph-index = 3

Forward Citations = 44(Granted Patents)


Company Filing History:


Years Active: 2014-2018

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovations of Frank Segrave

Introduction

Frank Segrave is an accomplished inventor based in Dublin, Ohio. He has made significant contributions to the field of pharmaceuticals, particularly in the development of enalapril compositions. With a total of three patents to his name, Segrave's work has had a notable impact on the treatment of various cardiovascular diseases.

Latest Patents

Segrave's latest patents focus on stable enalapril powder compositions for oral liquid formulations. These compositions are designed for the treatment of diseases such as hypertension, heart failure, and asymptomatic left ventricular dysfunction. The methods provided in these patents highlight the importance of effective oral liquid formulations in managing these health conditions.

Career Highlights

Throughout his career, Frank Segrave has worked with reputable organizations, including the University of Kansas Medical Center Research Institute and Silvergate Pharmaceuticals Inc. His experience in these institutions has allowed him to refine his expertise in pharmaceutical research and development.

Collaborations

Segrave has collaborated with notable colleagues, including Lian G. Rajewski and Roger A. Rajewski. These partnerships have contributed to the advancement of his research and the successful development of his patented innovations.

Conclusion

Frank Segrave's contributions to the field of pharmaceuticals, particularly through his patents on enalapril compositions, demonstrate his commitment to improving healthcare outcomes. His work continues to influence the treatment of cardiovascular diseases, showcasing the importance of innovation in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…